Previous 10 | Next 10 |
Landmark Bancorp Inc. (LARK) is expected to report for Q4 2023 BrightView Holdings Inc. (BV) is expected to report $0.02 for Q1 2024 Roper Technologies Inc. (ROP) is expected to report $4.33 for Q4 2023 Columbus McKinnon Corporation (CMCO) is expected to report $0.69 for Q3 2024 W...
The intended divestiture is expected to play an important role in Teva's “Pivot to Growth” strategy as it will allow Teva to focus on its core business strengths and on capital allocation towards growth engines and innovation Such intended divestiture of Teva’s API busine...
2024-01-30 15:43:59 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited (TEVA) Presents at J.P. Morgan 42nd Annual Global Healthcare Conference (Transcript) Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating) Teva Pharmaceutical Industries Limi...
2024-01-28 08:00:00 ET As the calendar transitions from January to February, the upcoming week promises a flood of earnings reports from some of the world's largest companies by market capitalization. Among the noteworthy releases are anticipated updates from tech giants Microsoft ( ...
2024-01-27 07:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-26 07:16:34 ET More on Cigna, CVS Health, etc. Humana: The $300 Level Could Get Taken Out In The Near Future Humana Inc. (HUM) Q4 2023 Earnings Call Transcript CVS Health: Back In The Buy Column Humana gets downgrade at Deutsche Bank as stock nears fo...
2024-01-23 15:00:40 ET More on GSK GSK plc (GSK) 42nd Annual JP Morgan Healthcare Conference (Transcript) AbbVie Vs. GSK: Dual Dominance In Pharma GSK - Greenshoots In The Horizon GSK sells off partial stake in Haleon for $1.2B GSK to sell 3.2% stake ...
2024-01-23 08:29:22 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited (TEVA) Presents at J.P. Morgan 42nd Annual Global Healthcare Conference (Transcript) Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating) Teva Pharmaceutical Industries Limi...
2024-01-23 07:15:02 ET Jefferies analyst issues BUY recommendation for TEVA on January 23, 2024 07:44AM ET. The previous analyst recommendation was Positive. TEVA was trading at $11.49 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...
2024-01-22 19:45:34 ET Summary Catalyst Pharmaceuticals is a biopharmaceutical company specializing in treatments for rare neurological and epileptic disorders. The company's main products are Firdapse and Fycompa, which make up the majority of its revenue. The launch of Agamr...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...